United States · Series C startup
7 rounds we have observed, with the 11 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Funding summaryUpdated 26 Oct 2026
$89Mraised across 7 rounds since 2003, from 7 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
Redmile Group
New Leaf Venture Partners
Jennison Associates
Fidelity Management and Research Company
Tekla Capital Management
Partner Fund Management (PFM)From a historical funding recordSEC filing: $55M sold, first sale Jul 2015
Reported by finsmes.comSEC filing: $3.0M sold, first sale Dec 2009
No investor was named in the report.
From a historical funding recordSEC filing: $150K sold, first sale Oct 2009
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Domain AssociatesNew Leaf Venture Partners
Third Rock Ventures
Pappas Ventures
National Institutes of HealthRedmile Group
Slater Technology FundJennison AssociatesFidelity Management and Research CompanyTekla Capital ManagementMissing a round, or an investor who was in one? Tell us.
Afferent Pharmaceuticals's investors include Domain Associates, New Leaf Venture Partners, Third Rock Ventures, Pappas Ventures and National Institutes of Health, and 6 more on record.
Afferent Pharmaceuticals has raised $89M across 7 rounds since 2003.
Afferent Pharmaceuticals's most recent round was a Series C of $55M in Jul 2015.
Its most recent round, $55M in Jul 2015, is also its largest on record.
Afferent Pharmaceuticals's first round on record, in Aug 2003, was backed by National Institutes of Health.
Afferent Pharmaceuticals's latest named round is a Series C, in Jul 2015.
Afferent Pharmaceuticals is based in the United States.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United States ·